• Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About

Tag: HIV

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

Pascale Boulet - September 10, 2018

How patents, data exclusivity and SPCs interact to extend market exclusivity...

Pascale Boulet - July 10, 2018

Dolutegravir Patent Licences Can Provide Access To All

Ellen 't Hoen - July 26, 2017

Recent Posts

  • Wrapping up 2022 with some noteworthy medicines, law and policy events
  • The Waiver that Wasn’t: Is the pharma lobby responsible?
  • TRIPS, technology transfer and access to pandemic countermeasures: What the WHO  Pandemic Treaty must do
  • Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert Group on the Pandemic Treaty published by BMJ Global Health

Posts by Subject

Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine Data exclusivity Delinkage DNDi essential medicines list European Union evergreening Fair Pricing Gilead Hepatitis C IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir SPC The Netherlands transparency TRIPS Council TRIPS flexibilities TRIPS Waiver Truvada vaccines WHO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.
  • Home
  • Covid-19
  • Tools
    • Introduction to the Tools
    • Model Government Use Licences
    • Model Uses of Paragraph 7 or “LDC Waiver”
    • Special Compulsory Licences for Export of Medicines
    • Options for Regional Economic Communities
    • Voluntary Licences
  • TRIPS Flexibilities Database
  • Resources
    • Briefs & Briefing Documents
    • Publications
    • Tools
    • Useful Links
    • All Resources
  • Blog
  • About
 This work is licensed under Creative Commons.